



Washington State Health Care Authority
Prescription Drug Program

626 8th Ave SE, Olympia, WA 98501

<https://www.hca.wa.gov/about-hca/prescription-drug-program>

August 14, 2024

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective September 1, 2024:

Atopic Dermatitis reviewed 06/21/2023			
Ingredient Name	Label Name of Preferred Product	L&I	UMP
dupilumab	Dupixent [®] subcutaneous injection	Not participating	Yes
pimecrolimus	pimecrolimus cream		Yes
ruxolitinib	Opzelura [®] cream		Yes
tacrolimus	tacrolimus ointment		Yes
The effect of this recommendation is to make Opzelura [®] preferred on the WA PDL.			

Asthma Biologics reviewed 10/18/2024			
Ingredient Name	Label Name of Preferred Product	L&I	UMP
dupilumab	Dupixent [®] subcutaneous injection	Not participating	Yes
mepolizumab	Nucala [®] subcutaneous injection		Yes
omalizumab	Xolair [®] subcutaneous injection		Yes
The effect of this recommendation is no change to the WA PDL.			

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our [website](#).

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (360) 725-1188 or by email at leta.evaskus@hca.wa.gov.

Sincerely,

Donna Sullivan
Chief Pharmacy Officer
Clinical Quality and Care Transformation
Washington State Health Care Authority